Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial
Inhibition of the epidermal growth factor receptor (EGFR) signaling using the monoclonal antibodies (mAbs) cetuximab and panitumumab or tyrosine kinase inhibitors including afatinib and erlotinib are established therapeutic approaches for advanced non-small cell lung and colorectal carcinomas. Intensive studies of hematological and breast cancers have indicated the potential value of whole-transcriptome analysis using high-throughput technologies to gain insights into tumor biology and creation of prognostic and/or predictive models.
Source: Oral Oncology - Category: Cancer & Oncology Authors: Marco Siano, Vittoria Espeli, Nicolas Mach, Paolo Bossi, Lisa Licitra, Michele Ghielmini, Milo Frattini, Silvana Canevari, Loris De Cecco Source Type: research
More News: Biology | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Colorectal Cancer | Erbitux | Genetics | Head and Neck Cancer | Hematology | Non-Small Cell Lung Cancer | Oral Cancer | Study | Tarceva